-+ 0.00%
-+ 0.00%
-+ 0.00%

Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

Benzinga·08/19/2026 14:47:02
Listen to the news
Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.